Target intelligence / Profile preview

FK506-binding protein 12 F36V-tagged protein of interest (FKBP12(F36V)-POI)

Target
FKBP12(F36V)-POI
Molecular classification
Fusion protein, Peptidyl-prolyl cis-trans isomerase (mutant), Degradation substrate, Chemical genetic tool
01

Overview

The FKBP12F36V-tagged protein of interest is a synthetic substrate used in the degradation TAG (dTAG) system for rapid and reversible protein depletion. This system utilizes a mutant form of the FK506-binding protein 12 (FKBP12) containing a phenylalanine-to-valine substitution at residue 36, which creates a unique binding pocket for synthetic ligands (Nabet et al., 2018, Nature Chemical Biology). By fusing this tag to a protein of interest (POI) using CRISPR/Cas9 or transgene expression, researchers can target the POI for degradation using heterobifunctional dTAG molecules. These molecules recruit E3 ubiquitin ligases, such as Cereblon (CRBN) or Von Hippel-Lindau (VHL), to the tagged protein, inducing its ubiquitination and subsequent degradation by the 26S proteasome (Nabet et al., 2020, Nature Communications). This technology is primarily used for target validation in drug discovery, allowing for the study of the biological consequences of losing a specific protein's function in real-time. Unlike traditional genetic knockouts, the dTAG system provides temporal control and can distinguish between the scaffolding and enzymatic functions of a protein. The F36V mutation is critical as it allows the dTAG ligands to selectively bind the mutant tag over the endogenous, wild-type FKBP12 protein, minimizing off-target effects.

Other names
dTAG systemFKBP12 F36V fusion proteinFKBP12 mutant-tagged proteindegradation TAG
02

Mechanism of action

Recruitment of E3 ubiquitin ligases (e.g., CRBN or VHL) to the tagged protein via heterobifunctional small molecules (dTAG ligands), leading to polyubiquitination and subsequent proteasomal degradation.

03

Biological functions

Protein degradationChemical genetic toolTarget validationTemporal control of protein expression
04

Disease associations

Cancer (research)Genetic disorders (research)Neurodegenerative disease (research)
05

Safety considerations

Potential off-target degradation of endogenous proteinsCompetition with endogenous E3 ligase substratesImmunogenicity of the FKBP12(F36V) fusion tag in clinical applicationsPotential toxicity of dTAG ligands at high concentrations
06

Interacting drugs

dTAG-13

4 more in the full profile.

07

Biomarkers

Protein level of the protein of interest (POI)FKBP12(F36V) expression levelsUbiquitination status of the POI

Beyond the preview

Go deeper on FK506-binding protein 12 F36V-tagged protein of interest (FKBP12(F36V)-POI).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FK506-binding protein 12 F36V-tagged protein of interest (FKBP12(F36V)-POI).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call